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Activation of the renal transforming growth factor-b
(TGF-b) system likely mediates the excess production
of extracellular matrix in the diabetic kidney. To es-
tablish the role of the TGF-b system in type 2 diabetic
nephropathy, we examined the intrarenal localiza-
tion and expression of the TGF-b1 isoform, the TGF-b
type II receptor, and the Smad signaling pathway in
the 16-week-old db/db mouse, a genetic model of type
2 diabetes that exhibits mesangial matrix expansion,
glomerular basement membrane thickening, and re-
nal insufficiency that closely resemble the human
disease. Compared with its nondiabetic db/m litter-
mate, the db/db mouse showed significantly increased
TGF-b1 mRNA expression by in situ hybridization in
both glomerular and tubular compartments. Likewise,
TGF-b1 protein, by immunohistochemical staining,
was increased in both renal compartments, but the
fractional expression of TGF-b1 protein was less than
that of the mRNA in the glomerulus. In situ hybrid-
ization and immunohistochemical staining for the
TGF-b type II receptor revealed concordant and sig-
nificant increases of both mRNA and protein in the
glomerular and tubular compartments of diabetic an-
imals. Finally, immunohistochemistry showed prefer-
ential accumulation of Smad3 in the nuclei of glomeru-
lar and tubular cells in diabetes. The complementary
technique of Southwestern histochemistry using a la-
beled Smad-binding element demonstrated increased
binding of nuclear proteins to Smad-binding element,
indicating active signaling downstream of the TGF-b
stimulus. We therefore propose that the TGF-b system is
up-regulated at the ligand, receptor, and signaling lev-
els throughout the renal cortex in this animal model of
type 2 diabetes. Our findings suggest that the profibrotic
effects of TGF-b may underlie the progression to glo-
merulosclerosis and tubulointerstitial fibrosis that char-
acterize diabetic nephropathy. (Am J Pathol 2001,
158:1653–1663)
An expanding body of in vitro and in vivo studies impli-
cates the profibrotic cytokine, transforming growth fac-
tor-b (TGF-b), in the pathogenesis of diabetic kidney
disease.1 Increased amounts of TGF-b1 mRNA and pro-
tein have been demonstrated in the glomeruli and tubu-
lointerstitial compartments of diabetic patients with ne-
phropathy.2,3 In animal models of diabetes, the intrarenal
expression of TGF-b1 was similarly elevated at both the
mRNA and protein levels in the streptozotocin-induced
diabetic rat,4–6 the streptozotocin diabetic mouse,7 the
spontaneously diabetic BioBreeding rat, and the nono-
bese diabetic mouse.8 In cell culture experiments, high
glucose has been shown to stimulate the production of
TGF-b1 by various renal cell lines derived from the glo-
merular and tubulointerstitial compartments.9–14
In contrast to TGF-b, the expression of the TGF-b
receptors has not been as extensively examined. Only a
handful of in vitro studies have demonstrated that high
ambient glucose stimulates TGF-b type II receptor
(TbRII) expression in cultured renal cells.15–17 In the
streptozotocin-diabetic mouse, we previously showed
that TbRII mRNA and protein, assessed by Northern and
Western blots, were increased in the renal cortex.7,17
The db/db mouse (C57BL/KsJ), a genetic model of
type 2 diabetes, exhibits clinical and histological features
Supported in part by the Juvenile Diabetes Foundation International (to
F. N. Z., M. I., and S. C.), and the National Institutes of Health (grants
DK-44513, DK-45191, and DK-54608 to F. N. Z.; training grant DK-07006,
and National Research Service Award to S. C.). S. W. H. and D. C. H are
visiting scholars at the University of Pennsylvania and are supported by
Yonsei University, and Hyonam Kidney Laboratory/Soon Chun Hyang
University, respectively, Seoul, Korea. M. C. Iglesias-de la Cruz is a
postdoctoral fellow at the University of Pennsylvania and is supported by
the Ministerio de Educacio´n y Cultura of Spain.
Accepted for publication January 23, 2001.
Address reprint requests to Fuad N. Ziyadeh, M.D., 700 Clinical Re-
search Building, Renal-Electrolyte and Hypertension Division, University
of Pennsylvania, 415 Curie Blvd., Philadelphia, PA 19104-6144. E-mail:
ziyadeh@mail.med.upenn.edu.
American Journal of Pathology, Vol. 158, No. 5, May 2001
Copyright © American Society for Investigative Pathology
1653
of diabetic nephropathy that track the human dis-
ease.18,19 This animal becomes hyperglycemic by 8
weeks of age and develops overt proteinuria and renal
insufficiency by 16 weeks of age. The kidneys show the
characteristic histological lesions of diabetic nephropa-
thy including mesangial matrix expansion and glomerular
basement membrane thickening. At the molecular level,
mRNAs encoding a1(IV) collagen and fibronectin are
overexpressed.20–22 We recently reported that chronic
treatment of db/db mice with a neutralizing anti-TGF-b
antibody successfully prevented mesangial matrix ex-
pansion and renal insufficiency,23 proving that the TGF-b
system plays an important role in the development of
diabetic nephropathy. However, the precise details of the
expression of TGF-b, its type II receptor, and the signal-
ing pathway were not delineated in that study.
The Smad family of proteins has recently been identi-
fied as a predominant signaling pathway by which TGF-b
activates the transcription of several well-known TGF-b-
inducible genes.24,25 Binding of TGF-b to its type II re-
ceptor and subsequent recruitment of the type I receptor
result in the phosphorylation and activation of two recep-
tor-regulated Smads (R-Smads), Smad2 and Smad3. Af-
ter associating with a common-Smad (co-Smad), Smad4,
the Smad complex translocates into the nucleus where it
cooperates with other transcription factors to coordinate
the expression of target genes.26 Because diabetes re-
sults in the activation of the renal TGF-b system, the
Smad pathway is probably activated in the diabetic state,
but this has not yet been shown either in vitro or in vivo.
The current study seeks to more fully characterize the
intrarenal TGF-b system in type 2 diabetes. The glomer-
ular and tubular distribution of TGF-b1 and its type II
receptor were assessed at the mRNA and protein levels
by in situ hybridization and immunohistochemistry, re-
spectively. Translocation of Smad3 into the nucleus and
nuclear binding activity to Smad-binding element (SBE)
were ascertained by immunohistochemistry and South-
western histochemistry, respectively. Our findings
present a more complete picture of how the ligand, re-
ceptor, and signaling components of the renal TGF-b
system may interact to promote the progression of dia-
betic kidney disease.
Materials and Methods
Experimental Animals and Design
The diabetic db/db and nondiabetic db/m mice were
purchased from Jackson Laboratory (Bar Harbor, ME).
Six animals from each group were killed at 16 weeks of
age when the db/db mice have been overtly hyperglyce-
mic and were likely to have developed diabetic nephrop-
athy. Blood glucose was measured by the glucose oxi-
dase technique (Sigma, St. Louis, MO), and serum
creatinine was measured by a colorimetric assay (Sig-
ma). The left kidney from each mouse was excised, bi-
sected, and processed in fixative solutions as described
below.
Each kidney was processed into frozen sections for in
situ hybridization and into paraffin sections for periodic
acid-Schiff staining, immunohistochemistry, and South-
western histochemistry. Selected kidneys from each
group were processed for ultrastructural examination as
described below.
Histological and Ultrastructural Examination
Formalin-fixed kidneys were embedded in paraffin, sec-
tioned at 5 mm, and stained with periodic acid-Schiff.
Thirty glomeruli were randomly selected from each ani-
mal, and the extent of extracellular mesangial matrix was
identified by periodic acid-Schiff-positive material in the
mesangium and factored by the glomerular tuft area.21
For ultrastructural evaluation, tissue was fixed in 3%
glutaraldehyde, postfixed in osmium tetroxide, and
stained with uranyl acetate and lead citrate. The speci-
men was thin-sectioned and examined under a transmis-
sion electron microscope. Electron microscopic pictures
were randomly taken at 31,000, 32,000, and 310,000
magnification in each group. With the computer program,
Image-Pro Plus 3.0 (Media Cybernetics, Silver Spring,
MD), the glomerular basement membrane thickness was
measured on high magnification. Mesangial cell size and
number were determined on low magnification.
Table 1. Characteristics of the Normal and Diabetic Mice
db/m
(n 5 6)
db/db
(n 5 6)
Plasma glucose (mg/dl) 120 6 7 450 6 26*
Body weight (g) 23 6 0.3 50 6 0.7*
Kidney weight (mg) 130 6 2 200 6 6*
Plasma creatinine (mg/dl) 0.3 6 0.02 0.6 6 0.06*
Mesangial matrix (% of glomerular tuft area)
Inner cortex 20.4 6 2.5 32.7 6 4.5*
Outer cortex 31.2 6 4.5 54.6 6 3.2*
Mesangial cell size (mm2) 342.0 6 13.6 377.4 6 10.2†
Mesangial cell number (per glomerular cross section) 12.5 6 1.4 13.3 6 2.3
GBM thickness (nm) 17.4 6 0.4 21.9 6 0.7*
Mice (non-diabetic db/m or diabetic db/db) at 16 weeks of age.
*P , 0.05.
†P 5 0.05 versus db/m.
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Immunohistochemical Staining of TGF-b1,
TbRII, and Smad3
Immunohistochemical stains for TGF-b1, TbRII, and
Smad3 were performed using a streptavidin biotin-stain-
ing method (Vector Laboratories, Burlingame, CA). After
removal of paraffin, endogenous peroxidase activity was
quenched by a 30-minute incubation with 0.3% H2O2 in
absolute methanol. The slides were placed in 10 mmol/L
citrate buffer (pH 6.0), microwaved for 10 minutes, and
cooled down to room temperature. Slides were then
placed in phosphate-buffered saline (PBS) for 15 minutes
followed by protein-blocking solution (Immunotech, Ce-
dex, France) for 30 minutes. Sections were incubated
overnight at 4°C with one of three primary antibodies as
follows: a polyclonal rabbit antibody against mouse TGF-
b1, a polyclonal rabbit antibody against mouse TbRII
(both Santa-Cruz Biotechnology, Santa Cruz, CA), and a
polyclonal rabbit antibody against mouse Smad3 (Zymed
Laboratory, South San Francisco, CA), all at 1:100 dilu-
tion. The same concentration of isotype-matched anti-
body of irrelevant specificity was used as a negative
control. After three 5-minute washes in PBS, a secondary
biotinylated anti-rabbit antibody (Vector Laboratories)
was added for 45 minutes at room temperature. After
three 5-minute washes in PBS, streptavidin-biotin perox-
idase (Vector Laboratories) was added for 45 minutes at
room temperature. The color reaction was developed
with the diaminobenzidine detection kit (Vector Labora-
tories) and counterstained with hematoxylin.
TGF-b1 and TbRII Riboprobe Preparation and
in Situ Hybridization
The cDNA probes encoding mouse TGF-b1 and TbRII
were synthesized by polymerase chain reaction using
murine kidney cDNA as template and specific oligonu-
cleotide primers based on the published cDNA se-
quences as previously described.7,9,27 The polymerase
chain reaction products were subcloned into pCRII TA
cloning vector (Invitrogen, Carlsbad, CA). The mouse
TGF-b1 cDNA was linearized with NotI for antisense and
HindIII for sense orientation, and the TbRII cDNA was
linearized with HindIII for antisense and NotI for sense
orientation. The transcription reaction using digoxigenin-
labeling of riboprobe was performed according to the
manufacturer’s instructions (Roche, Indianapolis, IN).
The labeling mixture consisted of 1 mg of template cDNA
(in 13 ml of water), 2 ml of NTP labeling mixture, 2 ml of
transcription buffer, 1 ml of RNase inhibitor, and 2 ml of T7
or SP6 polymerase. Transcription was performed for 2
hours at 37°C, followed by digestion with 2 ml of RNase-
free DNase for 15 minutes at 37°C and purification by
spin columns. For in situ hybridization, frozen kidney sec-
tions (5 mm) were overlaid with 30 ml of hybridization
buffer containing the labeled RNA probe and incubated
at 58°C overnight in a humid chamber. After hybridiza-
tion, sections were washed once in 23 standard saline
citrate (SSC) at room temperature, once in 23 SSC at
65°C, and once in 0.13 SSC at 65°C. Slides were equil-
ibrated with buffer I (100 mmol/L Tris-HCl, 150 mmol/L
NaCl, pH 7.5) for 5 minutes. Anti-digoxigenin antibody
conjugated to alkaline phosphatase (1:5,000) was ap-
plied to the slides, which were incubated in a humid
chamber for 2 hours at room temperature. After two
washes in buffer I for 15 minutes each, the sections were
equilibrated with developing buffer (100 mmol/L Tris, 100
mmol/L NaCl, 50 mmol/L MgCl2, pH 9.5) for 5 minutes.
The color reaction was developed using nitro blue tetra-
zolium (NBT/BCIP, Roche) according to the manufactur-
er’s instructions.
Southwestern Histochemistry
Southwestern histochemistry was performed according
to the literature with slight modifications.28 Complemen-
tary oligonucleotides containing a Smad-binding consen-
sus sequence29 were synthesized as follows: 59-GGAG-
Figure 1. Histological and ultrastructural characteristics in diabetic db/db
mice. Periodic acid-Schiff stain (original magnification, 3400) shows normal
appearance in outer cortex of 16-week-old control db/m mouse (A) and
increase in mesangial matrix and glomerular hypertrophy in diabetic db/db
mouse (B). Electron-microscopic image (original magnification, 31,000)
shows normal appearance of glomerulus in control db/m mouse (C) and
increased extracellular mesangial matrix without a change in cellularity in the
diabetic db/db mouse (D). The higher magnification (310,000) shows nor-
mal thickness of glomerular basement membrane of control db/m mouse (E)
and irregular thickening of glomerular basement membrane in diabetic db/db
mouse (F).
TGF-b and Smad Pathway Activation in the Diabetic Kidney 1655
AJP May 2001, Vol. 158, No. 5
TATGTCTAGACTGACAATGTAC-39. Paraffin-embedded
kidney sections were dewaxed and rehydrated. The
preparations were incubated with levamisole (Sigma
Chemical Co., St. Louis, MO) to inhibit endogenous alka-
line phosphatase activity and then fixed with 0.2% para-
formaldehyde for 30 minutes at 28°C. Sections were sub-
sequently digested with pepsin A (433 U/mg, Sigma) and
washed twice in HEPES-bovine serum albumin. The sec-
tions were incubated with 0.1 mg/ml DNase I in HEPES-
bovine serum albumin for 30 minutes at 30°C.
The labeled SBE probe, diluted to 100 pmol/L in
HEPES-bovine serum albumin containing 0.5 mg/ml poly
(dI-dC) (Amersham Pharmacia, Piscataway, NJ), was ap-
plied to each slide overnight at 37°C. A 100-fold unla-
beled SBE was used as competitive inhibitor. After incu-
bation in blocking solution (0.013 SSC, 0.01% sodium
dodecyl sulfate, 0.03% Tween 20, 0.1 mol/L maleic acid,
0.15 mol/L NaCl, pH 7.5), anti-digoxigenin antibody con-
jugated with alkaline phosphatase (1:250 in blocking so-
lution, Roche) was added overnight at 4°C. The color
reaction was developed using nitro blue tetrazolium
(NBT/BCIP, Roche) according to the manufacturer’s in-
structions.
Quantification of Immunohistochemistry, in Situ
Hybridization, and Southwestern Histochemistry
Data
Twenty glomeruli and 10 tubular areas, at 3400 or 3600
magnification, were randomly selected for analysis in
each of the experimental groups. The mRNA expression
and protein production of TGF-b1 and TbRII were mea-
sured by the density of the in situ hybridization signal and
immunohistochemical-positive staining, respectively, in
the glomerular and tubular compartments using the com-
puter program, Image-Pro Plus 3.0. The nuclear accumu-
lation of Smad3 protein and nuclear protein binding to
Figure 2. Renal expression of TGF-b1 mRNA by in situ hybridization in diabetic db/db mice. In situ hybridization of kidney sections with antisense TGF-b1
riboprobe (original magnification, 3400) shows minimal signal (arrow) in control db/m mouse (A) and increased hybridization signals in the mesangial area in
diabetic db/db mouse (B). Quantification of TGF-b1 mRNA expression shows higher glomerular TGF-b1 expression (C) and higher cortical tubular TGF-b1
expression (D) in diabetic db/db mice compared to db/m mice. Data are mean 6 SE; *, P , 0.05.
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SBE were assessed by manual tag counting using Im-
age-Pro Plus 3.0.
Statistical Analysis
Data are presented as mean 6 SE. Groups were com-
pared by unpaired Student’s t-test. P , 0.05 was consid-
ered significant.
Results
Clinical Characteristics, Glomerular Histology,
and Ultrastructural Findings
Clinical characteristics of the experimental mice are
shown in Table 1. The diabetic mice were frankly hyper-
glycemic by the end of the experimental period. At age
16 weeks, the body weights of the db/db mice were
significantly greater than those of the db/m mice. Kidney
weights were also significantly greater in the db/db mice.
However, average kidney-to-body weight ratios were pre-
dictably lower in the db/db group because the diabetic
animals were much heavier. The db/db mice developed
renal insufficiency as evidenced by the elevated plasma
creatinine concentration. To assess glomerulosclerosis,
we measured the glomerular fraction occupied by mes-
angial matrix and divided the analysis by location in the
inner or outer cortex, because glomeruli are normally
larger in the inner cortex. The mesangial matrix fraction
was significantly increased in both inner and outer corti-
ces in db/db compared with db/m mice (Figure 1, A and
B; Table 1). Ultrastructural examination of the kidney of
db/db mice revealed increased mesangial extracellular
Figure 3. Renal expression of TGF-b1 protein by immunohistochemistry in diabetic db/db mice. Immunohistochemical stain of kidney sections (original
magnification, 3400) shows that TGF-b1 protein is stained in glomerular and tubular areas (arrow) in the db/m mouse (A) and that TGF-b1 protein is slightly
increased in glomerular and tubular areas with strong juxtaglomerular signal (arrow) in the diabetic db/db mouse (B). Quantification of TGF-b1 protein
expression in glomerular (C) and in tubular areas (D) in normal db/m and diabetic db/db mice. Data are mean 6 SE.
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matrix (Figure 1, C and D). The size of the mesangial cell
was slightly increased in db/db mice compared with
db/m mice. However, the number of mesangial cells in
the glomerulus was not different between the two
groups (Table 1). In db/db mice, the glomerular base-
ment membrane was thickened with irregular distortions
and multifocal foot process effacement of the podocytes
(Figure 1, E and F; Table 1). No electron dense deposits
were seen.
Intrarenal TGF-b1 mRNA and Protein
Localization
To evaluate the renal TGF-b system in the db/db mouse,
we first examined the expression of TGF-b1 mRNA by in
situ hybridization. As shown in Figure 2, A and B, the
expression of TGF-b1 mRNA was significantly increased
in the glomerular tuft, in a mesangio-capillary pattern, in
db/db mice compared with controls (Figure 2C). Although
the staining of TGF-b1 mRNA was weaker in the cortical
tubules of both nondiabetic and diabetic mice, formal
quantitative analysis revealed a significant increase in the
tubular TGF-b1 mRNA in db/db versus db/m mice as well
(Figure 2D).
Immunohistochemistry localized the TGF-b1 protein
predominantly to the proximal and distal tubules rather
than the glomeruli in nondiabetic mice (Figure 3A). In
diabetic mice, the intensity of staining in the tubules was
slightly but not significantly increased (Figure 3, A and B).
In addition, the glomerular staining was particularly prom-
inent in the juxtaglomerular areas of diabetic mice (Figure
3, B versus A). Although the db/db group displayed in-
creased TGF-b1 protein in both glomerular and tubular
compartments, these differences did not reach statistical
significance when compared with the db/m group (Figure 3,
C and D). Thus, the relative changes in the quantity of
Figure 4. Renal expression of TbRII mRNA by in situ hybridization in diabetic db/db mice. In situ hybridization of kidney sections with antisense TbRII riboprobe
(original magnification, 3400) in control db/m mouse (A) and in diabetic db/db mouse (B) shows increased hybridization signal (arrow) in the glomerular and
tubular areas in the diabetic db/db mouse. Quantification of TbRII mRNA expression shows higher glomerular TbRII expression (C) and higher tubular TbRII
expression (D) in diabetic db/db mice compared to db/m mice. Data are mean 6 SE; *, P , 0.05.
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TGF-b1 protein in the diabetic mouse were less pro-
nounced than the changes in the TGF-b1 mRNA discussed
above.
Intrarenal TbRII mRNA and Protein Localization
Whereas TGF-b1 mRNA staining was stronger in the
glomeruli than in the tubules, TbRII mRNA staining was
stronger in the tubules than in the glomeruli of both
groups of mice (Figure 4, A and B). Quantitatively, the
expression of TbRII mRNA within the tubules was clearly
and significantly increased in db/db mice (Figure 4D), but
the expression of TbRII mRNA within the glomeruli was
also significantly increased in db/db compared with con-
trol db/m mice (Figure 4C).
By immunohistochemistry, TbRII protein was primarily
distributed in the distal tubules (Figure 5, C and D), and
overall expression was markedly enhanced in diabetic
versus nondiabetic mice (Figure 5, A–D). Like its mRNA
counterpart, the TbRII protein stained more heavily in the
Figure 5. Renal expression of TbRII protein by immunohistochemistry in diabetic db/db mice. Immunohistochemical stain of kidney sections for TbRII protein
(original magnification, 3600) in control db/m mouse (A and C) and in diabetic db/db mouse (B and D) shows increased staining (arrow) in the glomerular and
tubular cytoplasm and in the plasma membrane of the diabetic db/db mouse. Quantification of TbRII protein expression shows increased glomerular TbRII
expression (E) and increased tubular TbRII expression (F) in diabetic db/db mice compared to db/m mice. Data are mean 6 SE; *, P , 0.05.
TGF-b and Smad Pathway Activation in the Diabetic Kidney 1659
AJP May 2001, Vol. 158, No. 5
tubular than in the glomerular compartments (Figure 5, D
versus B). Compared with the nondiabetic controls, the
diabetic mice displayed significantly greater staining
densities for TbRII protein in the tubules as expected
(Figure 5F) but also in the glomeruli (Figure 5E).
Nuclear Accumulation of Smad3
Recent pieces of evidence have demonstrated that Smad
proteins are important intracellular transducers of TGF-b
signaling.26 Therefore, we hypothesized that the Smad
pathway is activated in the diabetic kidney, and Smad
proteins would accumulate in renal cell nuclei. Immuno-
histochemical staining for Smad3 protein revealed dif-
fusely increased cytoplasmic and nuclear staining in
db/db mice compared with controls. By visual inspection,
nuclear staining of Smad3 protein was noticeably more
prominent in the db/db mice (Figure 6, B and E) com-
pared with db/m mice (Figure 6, A and D). By manual tag
counting, Smad3 nuclear staining was confirmed to be
significantly increased in both glomeruli and tubules in
db/db mice (Figure 6, G and H).
Activation of Nuclear Protein Binding to SBE
After Smad3 is activated in response to TGF-b, it trans-
locates to the nucleus where it binds to certain DNA sites
such as the SBE.29 We next examined whether nuclear
protein binding to SBE is enhanced in the diabetic kid-
ney. To evaluate the extent of SBE binding, we performed
Southwestern histochemistry.28,30 As shown in Figure 7,
labeled SBE localized more often to the nuclei of both
Figure 6. Nuclear expression of Smad3 protein by immunohistochemistry in diabetic db/db mice. Immunohistochemical stain for Smad3 protein (original
magnification, 3600) shows patchy glomerular (A) and tubular (D) cytoplasmic staining with scanty nuclear accumulation in control db/m mouse, and strong
diffuse glomerular (B) and tubular (E) cytoplasmic staining with intense nuclear accumulation (arrow) in diabetic db/db mouse. The incubation with substituted
isotype-matched antibody shows negative staining in glomerulus and tubule (C and F). Quantification of Smad3 protein expression in glomeruli (G) and in tubules
(H) shows significantly increased nuclear signal in diabetic db/db mice compared to db/m mice. Data are mean 6 SE; *, P , 0.05.
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tubular (Figure 7, A and B) and glomerular (Figure 7, C
and D) cells in db/db mice than in db/m controls. Figure
7, E and F, which quantitate the percentage of glomerular
or tubular cells that display nuclear SBE binding, showed
significant increases in the nuclear localization of SBE in
diabetic compared with nondiabetic mice.
Discussion
In this study, we attempted to provide a more complete
description of the components of the renal TGF-b system
in the db/db mouse, a genetic model of type 2 diabetes.
The renal cortical parenchyma exhibited increases in
both TGF-b1 and TbRII in the glomerular and tubular
compartments. In addition, we demonstrated that the
nuclear accumulation of Smad3 and the nuclear protein
binding to SBE were increased in parallel with the mes-
angial expansion and glomerular hypertrophy that typi-
cally develop in the diabetic db/db mouse.
It has been well established that the TGF-b cytokine is
up-regulated in the kidney of animal models of type 1
diabetes. The intrarenal expression of TGF-b mRNA, as-
Figure 7. Nuclear binding activity to SBE by Southwestern histochemistry in diabetic db/db mice. Southwestern histochemistry with SBE (original magnification,
3600) shows patchy, scanty tubular cytoplasmic staining with sparse nuclear (arrow) accumulation in control db/m mouse (A and C) and strong nuclear
accumulation (arrow) in tubular and glomerular cells in diabetic db/db mouse (B and D). Quantification of nuclear SBE staining in glomerulus (E) and in tubules
(F) shows significantly increased binding in diabetic db/db mice compared to db/m mice. Data are mean 6 SE; *, P , 0.05.
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sessed by Northern analysis or reverse transcriptase-
polymerase chain reaction of whole kidney RNA, is in-
creased in streptozotocin-induced diabetic animals.4,5,7
Using immunohistochemistry and in situ hybridization,
Park and colleagues6 reported that the TGF-b protein
and mRNA were increased in the glomerular and inter-
stitial compartments during the early stages of streptozo-
tocin diabetes in rats. Our group has shown with Northern
analysis that the expression of renal TGF-b1 mRNA is
increased in the BioBreeding rat and the nonobese dia-
betic mouse, other models of type 1 diabetes.8 Together,
these results strongly support a pathogenic role for this
cytokine in type 1 diabetic nephropathy.
The role of TGF-b has not been as extensively studied
in type 2 diabetic nephropathy. One study found by
immunohistochemistry that the TGF-b1 protein was in-
creased in the renal cortex of the Otsuka-Long-Evans-
Tokushima-Fatty rat, another model of type 2 diabetes.31
Another group showed that TGF-b was overexpressed in
the glomeruli of db/db mice in association with increased
expression of fibronectin and type IV collagen.22 Simi-
larly, the present study demonstrated that the expression
of TGF-b1 mRNA, assessed by in situ hybridization, was
markedly enhanced in the glomeruli of db/db mice. Al-
though this finding seems to conflict with our previous
study in which Northern analysis of whole kidney RNA
failed to detect an increase of TGF-b1 mRNA in db/db
mice versus control,32 these disparities may be recon-
ciled if one considers that TGF-b1 overexpression oc-
curred predominantly in the glomerular compartment
only. Hybridization signals for TGF-b1 mRNA were also
increased in the cortical tubular compartment between
diabetic and nondiabetic groups, but the staining was
patchy and irregular. Furthermore, the renal medulla did
not show any increase in TGF-b1 expression by in situ
hybridization (data not shown). Because glomeruli com-
prise ,10% of the renal parenchyma, the local increase
in glomerular TGF-b1 was masked by the lack of increase
in tubular and medullary TGF-b1 when whole kidney RNA
was examined. In addition, Northern analysis of the whole
kidney may not be sensitive enough to resolve small
differences in message expression in the various renal
compartments.
The marked increase in glomerular TGF-b1 mRNA,
however, did not result in a proportional increase in
TGF-b1 protein. This contrasts with the situation in type 1
diabetic animals that show significant elevations of both
TGF-b1 message and protein in the glomerulus.7 The
answer may lie with insulin, which has metabolic and
growth-promoting effects on the kidney in diabetes.33,34
We speculate that the hyperinsulinemia of type 2 diabe-
tes, absent in type 1, may inhibit the translation of TGF-b1
mRNA to protein. In fact, preliminary work on cultured
renal tubular cells has revealed that exogenous insulin
may alter the production of TGF-b1 protein through a
posttranscriptional mechanism.35,36
On the other hand, TbRII protein was up-regulated in
accord with the mRNA expression in both glomeruli and
tubules of the diabetic mice. These findings are consis-
tent with our previous study using Western and Northern
analyses of whole kidney tissue.23,32 In experimental di-
abetic conditions, the up-regulation of TbRII by high glu-
cose may sensitize the mesangial cell to the effects of
exogenous TGF-b1, which will considerably enhance its
type IV collagen production for example.17 Extrapolated
to the in vivo situation, these findings suggest that in-
creased TbRII expression may enhance the responsive-
ness to TGF-b, thus accentuating the extracellular matrix
accumulation in the kidneys of db/db mice.
Interestingly, nuclear accumulation of Smad3 and nu-
clear protein binding to SBE were increased in the kidney
of diabetic db/db mice. To our knowledge, these in vivo
observations are the first to prove that the specific down-
stream signaling pathway of TGF-b is activated in the
kidney in diabetes. After the binding of the TGF-b ligand,
Smad3 is phosphorylated and translocates into the nu-
cleus where it participates in the transcriptional regula-
tion of TGF-b target genes.26 Several TGF-b target genes
relevant to renal fibrosis, such as plasminogen activator
inhibitor PAI-1 and type I collagen, have been reported to
be regulated by Smad3 through Smad binding sites in
their promoters.37–39 Furthermore, Smad proteins have
been shown to interact with other transcription factors,
such as activator protein-1 and the family of cAMP-re-
sponsive element-binding proteins, which are required
for TGF-b-induced transcription of other fibrosis-related
genes.26,40,41 Although the precise involvement of the
Smad pathway in the regulation of extracellular matrix
proteins needs to be clarified, it is possible that the
activation of the Smad pathway leads to up-regulation of
not only type I collagen but also other extracellular matrix
proteins.
Our histological observations and their quantitation
prove that the critical components of the TGF-b system
are up-regulated throughout the renal cortex of the db/db
mouse model of type 2 diabetes. Although the level of
TGF-b1 protein was variably increased, the expression of
TbRII was particularly pronounced in both glomerular
and tubular compartments of the renal cortex, and this
translated into the downstream activation of Smad3, an
important element of the TGF-b signaling system. Given
the well-known prosclerotic effects of TGF-b, these find-
ings strongly support a central role for the TGF-b system
in the pathogenesis of glomerulosclerosis and tubuloin-
terstitial fibrosis in the nephropathy of type 2 diabetes.
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